PMID: 11606174Oct 19, 2001Paper

Extreme altitude mountaineering and Type 1 diabetes; the Diabetes Federation of Ireland Kilimanjaro Expedition

Diabetic Medicine : a Journal of the British Diabetic Association
K MooreC Thompson

Abstract

To examine the effects of extreme altitude mountaineering on glycaemic control in Type 1 diabetes, and to establish whether diabetes predisposes to acute mountain sickness (AMS). Fifteen people with Type 1 diabetes and 22 nondiabetic controls were studied during the Diabetes Federation of Ireland Expedition to Kilimanjaro. Daily insulin requirements, blood glucose estimations and hypoglycaemic attacks were recorded in diaries by the people with diabetes. The performance of blood glucose meters at altitude was assessed using standard glucose solutions. Symptoms of acute mountain sickness were recorded daily by people with diabetes and by the nondiabetic controls using the Lake Louise Scoring Charts. The expedition medical team recorded the incidence of complications of altitude and of diabetes. The final height attained for each individual was recorded by the expedition medical team and verified by the expedition guides. The final altitude ascended was lower in the diabetic than the nondiabetic group (5187 +/- 514 vs. 5654 +/- 307 m, P = 0.001). The mean daily insulin dose was reduced from 67.1 +/- 28.3-32.9 +/- 11.8 units (P < 0.001), but only 50% of recorded blood glucose readings were within the target range of 6-14 mmol/L. T...Continue Reading

References

Aug 1, 1979·The American Journal of Medicine·P H Hackett, D Rennie
Oct 13, 1990·BMJ : British Medical Journal·M MaggioriniO Oelz
Sep 1, 1989·The Diabetes Educator·B P GiordanoG J Klingensmith
Nov 22, 2000·Clinical Journal of Sport Medicine : Official Journal of the Canadian Academy of Sport Medicine·D B SpeedyS Safih

❮ Previous
Next ❯

Citations

May 8, 2002·Diabetes/metabolism Research and Reviews
Mar 21, 2012·Diabetes Technology & Therapeutics·Peter AdolfssonJohan Jendle
Jul 26, 2013·Diabetes Technology & Therapeutics·Christina SchmidGuido Freckmann
Aug 28, 2010·Journal of Applied Physiology·Cuneyt YilmazConnie C W Hsia
Nov 26, 2010·PloS One·Pieter de MolHenk J G Bilo
May 29, 2014·Travel Medicine and Infectious Disease·Shmuel StienlaufEli Schwartz
Mar 18, 2005·High Altitude Medicine & Biology·Conxita Leal
Sep 27, 2013·High Altitude Medicine & Biology·Paul Richards, David Hillebrandt
Jan 16, 2010·Journal of Travel Medicine·Kelly MieskeTimothy O'Brien
Sep 17, 2009·Pediatric Diabetes·Kenneth RobertsonMichael C Riddell
Jan 24, 2008·Pediatric Diabetes·Kenneth RobertsonRagnar Hanas
Sep 16, 2011·Diabetic Medicine : a Journal of the British Diabetic Association·J J VallettaC D Byrne
May 13, 2015·Diabetic Medicine : a Journal of the British Diabetic Association·S MohajeriM C Riddell
Jul 26, 2014·Diabetes Care·Pieter de MolCees J Tack
Jan 9, 2013·Journal of Diabetes Science and Technology·Peter AdolfssonJohan Jendle
Apr 6, 2016·Journal of Diabetes Science and Technology·Michael ErbachOliver Schnell
Jun 26, 2018·QJM : Monthly Journal of the Association of Physicians·Petros ThomakosAsimina Mitrakou
Nov 29, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·N S KalsonM D Earl
Oct 10, 2008·Journal of the American Society of Nephrology : JASN·Andrew M LuksErik R Swenson
Aug 5, 2004·Medicine and Science in Sports and Exercise·Paola PavanAngelo Avogaro
Jun 10, 2019·Practical Neurology·Marieke Cornelia Johanna DekkerWilliam Patrick Howlett
May 5, 2020·Journal of Paediatrics and Child Health·Natee SakornyutthadejPreamrudee Poomthavorn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.